D. W. Kim

3.4k total citations
9 papers, 592 citations indexed

About

D. W. Kim is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, D. W. Kim has authored 9 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in D. W. Kim's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). D. W. Kim is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). D. W. Kim collaborates with scholars based in United States, Italy and South Korea. D. W. Kim's co-authors include Timothy P. Hughes, Giuseppe Saglio, Andreas Hochhaus, Richard A. Larson, Beatriz Moiraghi, Rick E. Blakesley, Gabriel Étienne, Neil J. Gallagher, Mineo Kurokawa and Richard E. Clark and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and Haematologica.

In The Last Decade

D. W. Kim

9 papers receiving 585 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
D. W. Kim 507 411 261 124 67 9 592
Ladan Duvillié 385 0.8× 257 0.6× 131 0.5× 95 0.8× 66 1.0× 19 491
Phillipp D. Le Coutre 239 0.5× 162 0.4× 120 0.5× 89 0.7× 45 0.7× 12 323
Hyacinthe Johnson‐Ansah 353 0.7× 293 0.7× 161 0.6× 90 0.7× 31 0.5× 18 414
Lotta Ohm 355 0.7× 283 0.7× 147 0.6× 87 0.7× 32 0.5× 10 424
Marc Spentchian 198 0.4× 132 0.3× 92 0.4× 67 0.5× 134 2.0× 12 387
Mark Davis‐Lorton 226 0.4× 737 1.8× 297 1.1× 39 0.3× 113 1.7× 37 864
Mindaugas Jurgutis 281 0.6× 373 0.9× 137 0.5× 62 0.5× 203 3.0× 7 447
Ferdinando Porretto 177 0.3× 129 0.3× 97 0.4× 39 0.3× 66 1.0× 24 443
Elena Mishchenko 291 0.6× 384 0.9× 159 0.6× 58 0.5× 220 3.3× 12 461
Tianna Dauses 483 1.0× 184 0.4× 14 0.1× 94 0.8× 318 4.7× 8 630

Countries citing papers authored by D. W. Kim

Since Specialization
Citations

This map shows the geographic impact of D. W. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. W. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. W. Kim more than expected).

Fields of papers citing papers by D. W. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. W. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. W. Kim. The network helps show where D. W. Kim may publish in the future.

Co-authorship network of co-authors of D. W. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of D. W. Kim. A scholar is included among the top collaborators of D. W. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. W. Kim. D. W. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Seymour, John F., D. W. Kim, Abebe Haregewoin, et al.. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4(8). e238–e238. 56 indexed citations
2.
Angelini, Sabrina, Simona Soverini, Gloria Ravegnini, et al.. (2012). Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 98(2). 193–200. 93 indexed citations
3.
Larson, Richard A., Andreas Hochhaus, Timothy P. Hughes, et al.. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 26(10). 2197–2203. 323 indexed citations
4.
Coutre, Philipp D. le, Jörge E. Cortes, Francis J. Giles, et al.. (2012). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 27(4). 907–913. 16 indexed citations
5.
6.
Shah, Neha, D. W. Kim, Hagop M. Kantarjian, et al.. (2007). Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034. Journal of Clinical Oncology. 25(18_suppl). 7004–7004. 24 indexed citations
7.
Mueller, Martin, Susan Branford, Jerry Radich, et al.. (2007). Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. Journal of Clinical Oncology. 25(18_suppl). 7024–7024. 5 indexed citations
8.
Talpaz, Moshe, Jane F. Apperley, D. W. Kim, et al.. (2006). Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study. Journal of Clinical Oncology. 24(18_suppl). 6526–6526. 15 indexed citations
9.
Cortes, Jörge E., D. W. Kim, Gianantonio Rosti, et al.. (2006). Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study. Journal of Clinical Oncology. 24(18_suppl). 6529–6529. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ladan Duvillié Breakdown of academic impact, for papers by Phillipp D. Le Coutre Breakdown of academic impact, for papers by Hyacinthe Johnson‐Ansah Breakdown of academic impact, for papers by Lotta Ohm Breakdown of academic impact, for papers by Marc Spentchian Breakdown of academic impact, for papers by Mark Davis‐Lorton Breakdown of academic impact, for papers by Mindaugas Jurgutis Breakdown of academic impact, for papers by Ferdinando Porretto Breakdown of academic impact, for papers by Elena Mishchenko Breakdown of academic impact, for papers by Tianna Dauses
Rankless by CCL
2026